🇺🇸 FDA

Intelligence · Clinical Pipeline

RIGEL PHARMACEUTICALS Pipeline

All ClinicalTrials.gov programs at RIGEL PHARMACEUTICALS — phase, modality, and trial IDs.

Programs
26

Quick answer

RIGEL PHARMACEUTICALS has 26 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Fostamatinib

    RIGEL PHARMACEUTICALS INC

    Hidradenitis Suppurativa

    phase 2 small molecule completed

    1 trial

  2. Fostamatinib

    RIGEL PHARMACEUTICALS INC

    Myelofibrosis

    phase 2 small molecule terminated

    1 trial

  3. Fostamatinib 150 mg

    RIGEL PHARMACEUTICALS INC

    IGA Nephropathy

    phase 2 small molecule completed

    1 trial

  4. Fostamatinib 150 mg bid

    RIGEL PHARMACEUTICALS INC

    Warm Antibody Autoimmune Hemolytic Anemia

    phase 2 small molecule completed

    1 trial

  5. Fostamatinib Disodium

    RIGEL PHARMACEUTICALS INC

    T Cell Lymphoma

    phase 2 small molecule completed

    1 trial

  6. Fostamatinib Disodium (R935788)

    RIGEL PHARMACEUTICALS INC

    Systemic Lupus Erythematosus

    phase 2 small molecule terminated

    1 trial

  7. Fostamatinib Disodium / R935788

    RIGEL PHARMACEUTICALS INC

    Purpura, Thrombocytopenic, Idiopathic

    phase 2 small molecule completed

    1 trial

  8. Fostamatinib Disodium tablet 100 mg

    RIGEL PHARMACEUTICALS INC

    IGA Nephropathy

    phase 2 small molecule terminated

    1 trial

  9. Fostamatinib disodium (R935788)

    RIGEL PHARMACEUTICALS INC

    Rheumatoid Arthritis

    phase 2 small molecule completed

    2 trials

  10. LY3871801

    RIGEL PHARMACEUTICALS INC

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  11. Olutasidenib

    RIGEL PHARMACEUTICALS INC

    Mutant IDH1 Inhibitor Olutasidenib

    phase 2 small molecule active

    1 trial

  12. Olutasidenib

    RIGEL PHARMACEUTICALS INC

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  13. Olutasidenib

    RIGEL PHARMACEUTICALS INC

    Chronic Myelomonocytic Leukemia

    phase 2 small molecule terminated

    1 trial

  14. Olutasidenib

    RIGEL PHARMACEUTICALS INC

    Myelodysplastic Syndromes

    phase 2 small molecule active

    1 trial

  15. Olutasidenib

    RIGEL PHARMACEUTICALS INC

    Targeted Therapy

    phase 2 small molecule active

    1 trial

  16. Olutasidenib + TMZ

    RIGEL PHARMACEUTICALS INC

    High Grade Glioma

    phase 2 small molecule active

    1 trial

  17. Placebo

    RIGEL PHARMACEUTICALS INC

    Acute Respiratory Distress Syndrome

    phase 2 small molecule active

    1 trial

  18. Placebo

    RIGEL PHARMACEUTICALS INC

    Asthma

    phase 2 small molecule completed

    1 trial

  19. R348 Ophthalmic Solution, 0.2%

    RIGEL PHARMACEUTICALS INC

    Chronic Graft-versus-host Disease

    phase 2 small molecule completed

    1 trial

  20. R348 Ophthalmic Solution, 0.2%

    RIGEL PHARMACEUTICALS INC

    Keratoconjunctivitis Sicca

    phase 2 small molecule completed

    2 trials

  21. R788

    RIGEL PHARMACEUTICALS INC

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  22. R906289 Monosodium (R289 Na)

    RIGEL PHARMACEUTICALS INC

    Low Risk Myelodysplastic Syndromes

    phase 2 small molecule active

    1 trial

  23. R926112

    RIGEL PHARMACEUTICALS INC

    Rhinitis, Allergic, Seasonal

    phase 2 small molecule completed

    1 trial

  24. R932333

    RIGEL PHARMACEUTICALS INC

    Lupus Erythematosus, Discoid

    phase 2 small molecule completed

    1 trial

  25. Ruxolitinib

    RIGEL PHARMACEUTICALS INC

    Coronavirus

    phase 2 small molecule completed

    1 trial

  26. fostamatinib

    RIGEL PHARMACEUTICALS INC

    Lymphoma

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many pipeline programs does RIGEL PHARMACEUTICALS have?

26 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.